GGrantIndex
← Leaderboards

Opendra Narayan

University Of Kansas Medical Center

Google Scholar ↗PubMed ↗ORCID ↗
$11,863,425
Attributed
$11,863,425
Total exposure
13
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $3.8M · FY2005–07
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07

Funding mix

By agency

NIH$24,827,013 · 14

By mechanism

P20$13,837,618 · 4
R01$10,702,711 · 6
P51$286,684 · 4

Top collaborators

No co-investigators on record.

Most similar at University Of Kansas Medical Center

Same institution · by research overlap

Others in their field

Top investigators on “Simian Immunodeficiency Virus”

Research focus

Simian Immunodeficiency VirusAids VaccinesNonhuman Therapy EvaluationTissue /Cell CultureDisease /Disorder ModelHuman Immunodeficiency Virus 1Helper T LymphocyteAids TherapyAntiaids AgentLive VaccineVirus ReplicationVirus Infection MechanismMacaca MulattaEnzyme Linked Immunosorbent AssayMacacaCellular ImmunityRecombinant VirusBiological ModelsHost Organism InteractionAids /Hiv NeuropathyAntisense Nucleic AcidCytokine ReceptorsNeuropathologyChemokine

Grant awards (32)

COBRE KS: NOVEL APPROACHES TO CONTROL MICROBIAL PATHOGENS: ADMINISTRATIVE CORE$322,080
P20 · FY2007 · RR · contact PI
Novel Approaches for the Control of Microbial Pathogens$2,209,322
P20 · FY2006 · RR · contact PI
A New DNA Vaccine Against HIV Disease in Macaques$623,517
R01 · FY2006 · AI · contact PI
COBRE KS: NOVEL APPROACHES TO CONTROL MICROBIAL PATHOGENS: ADMINISTRATIVE CORE$324,283
P20 · FY2006 · RR · contact PI
Safety and Efficacy of SHIV Vaccine in Macaques$150,174
R01 · FY2006 · AI · contact PI
SAFETY AND EFFICACY OF SHIV VACCINE IN MACAQUES$59,665
P51 · FY2006 · RR · contact PI
NOVEL APPROACHES FOR CONTROL OF MICROBIAL PATHOGENS$2,178,838
P20 · FY2005 · RR
Safety and Efficacy of SHIV Vaccine in Macaques$746,982
R01 · FY2005 · AI
A New DNA Vaccine Against HIV Disease in Macaques$621,316
R01 · FY2005 · AI
COBRE KS: NOVEL APPROACHES TO CONTROL MICROBIAL PATHOGENS: ADMINISTRATIVE CORE$227,667
P20 · FY2005 · RR
NOVEL APPROACHES FOR CONTROL OF MICROBIAL PATHOGENS$2,196,527
P20 · FY2004 · RR
Safety and Efficacy of SHIV Vaccine in Macaques$729,605
R01 · FY2004 · AI
A New DNA Vaccine Against HIV Disease in Macaques$584,366
R01 · FY2004 · AI
SHIV MACAQUE MODEL OF ORAL IMMUNIZATION AGAINST HIV$91,436
P51 · FY2004 · RR
SAFETY AND EFFICACY OF SHIV VACCINE IN MACAQUES$51,707
P51 · FY2004 · RR
NOVEL APPROACHES FOR CONTROL OF MICROBIAL PATHOGENS$2,123,599
P20 · FY2003 · RR
Safety and Efficacy of SHIV Vaccine in Macaques$712,734
R01 · FY2003 · AI
MACAQUE MODEL OF THERAPEUTIC IMMUNIZATION AGAINST HIV$690,390
R01 · FY2003 · RR
NEUROPATHOGENESIS AND THERAPY OF SHIV-KU INFECTION$600,247
R01 · FY2003 · NS
SHIV MACAQUE MODEL OF ORAL IMMUNIZATION AGAINST SEXUALLY TRANSMITTED HIV$83,876
P51 · FY2003 · RR
NOVEL APPROACHES FOR CONTROL OF MICROBIAL PATHOGENS$2,135,999
P20 · FY2002 · RR
Safety and Efficacy of SHIV Vaccine in Macaques$697,674
R01 · FY2002 · AI
MACAQUE MODEL OF THERAPEUTIC IMMUNIZATION AGAINST HIV$670,280
R01 · FY2002 · RR
NEUROPATHOGENESIS AND THERAPY OF SHIV-KU INFECTION$571,692
R01 · FY2002 · NS
NOVEL APPROACHES FOR CONTROL OF MICROBIAL PATHOGENS$2,119,303
P20 · FY2001 · RR
MACAQUE MODEL OF THERAPEUTIC IMMUNIZATION AGAINST HIV$665,756
R01 · FY2001 · RR
NEUROPATHOGENESIS AND THERAPY OF SHIV-KU INFECTION$581,351
R01 · FY2001 · NS
NEUROPATHOGENESIS AND THERAPY OF SHIV-KU INFECTION$50,000
R01 · FY2001 · NS
MACAQUE MODEL OF THERAPEUTIC IMMUNIZATION AGAINST HIV$631,805
R01 · FY2000 · RR
NEUROPATHOGENESIS AND THERAPY OF SHIV-KU INFECTION$572,672
R01 · FY2000 · NS
ORAL IMMUNIZATION AGAINST SEXUALLY TRANSMITTED HIV$546,770
R01 · FY2000 · RR
PATHOGENESIS OF DEMENTIA IN SIV INFECTED MACAQUES$255,380
R01 · FY2000 · NS